• Diagnostics Partnerships, New Sequencers, Technical Advances From Illumina

    Bio-IT World | Francis deSouza, CEO of Illumina, gave his report this morning at the annual JP Morgan Healthcare Conference. Just days after terminating the planned merger between Illumina and Pacific Biosciences, deSouza was positive about Illumina’s outlook for 2020, announcing agreements with Roche and Genomics England as well as new sequencers and technical advances. “I have never been more excited about the opportunity for Illumina as we enter 2020,” he said.

    Jan 13, 2020

  • Avoid These Eight Costly Biospecimen Procurement Mistakes

    Bio-IT World Contributed Commentary | Every day counts when it comes to saving lives and generating revenue, especially when you’re trying to bring a drug, treatment, or diagnostic tool to market. Unfortunately, these processes often take a lot longer and cost a lot more than initially expected.

    Jan 10, 2020

  • Top 10 Stories of 2019: National Genomic Data Initiatives, AI’s Impact in Drug Development, And More

    Bio-IT World | As we head into 2020, we at Bio-IT World would like to take a moment and reflect on the groundbreaking achievements from this past year. In that spirit, here are the top 10 stories of 2019, ranked in order of popularity.

    Jan 9, 2020

  • How To Improve Biopharmaceutical Research Data Utilization?

    Bio-IT World Contributed Commentary | Many enterprise network security people intuitively put everything behind a firewall—even though it has been well-established that firewalls are big hindrance to high-speed data flows. There are a few reasons of poor data mobility and thus low utilization.

    Jan 8, 2020

  • Follow the Money: New Life Sciences Investment Firm, Funding for Deep Genomics, Verantos, TwinStrand Biosciences, More

    Bio-IT World  Perceptive Advisors launches a new venture capital fund for early-stage life sciences companies. Deep Genomics closes its series B round to fund its AI-powered drug discovery platform. Several molecular diagnostics companies receive funding to advance PCR platforms and companion diagnostics. TwinStrand Biosciences closes a Series A fund to create a new genomic sequencing technology, and more.

    Jan 7, 2020

  • Heart-In-A-Jar Platform Humanizing Preclinical Research

    Bio-IT World | Stem cell biotech company Novoheart has been bioengineering miniature human hearts as a platform for drug discovery and development for several to pharmaceutical firms, notably for human conditions without a good animal model for preclinical testing. Novoheart’s thumb-sized human “heart-in-a-jar” models can both contract and eject blood-like fluid, making it possible to measure how well the heart is pumping.

    Jan 6, 2020